Article
In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.
The EMBO journal - 2 Mar 2020
Annunziato Stefano, Lutz Catrin, Henneman Linda, Bhin Jinhyuk, Wong Kim, Siteur Bjørn, van Gerwen Bas, de Korte-Grimmerink Renske, Zafra Maria Paz, Schatoff Emma M, Drenth Anne Paulien, van der Burg Eline, Eijkman Timo, Mukherjee Siddhartha, Boroviak Katharina, Wessels Lodewyk Fa, van de Ven Marieke, Huijbers Ivo J, Adams David J, Dow Lukas E, Jonkers Jos
Abstract excerpt
Genetically engineered mouse models (GEMMs) of cancer have proven to be of great value for basic and translational research. Although CRISPR-based gene disruption offers a fast-track approach for perturbing gene function and circumvents certain limitations of standard GEMM development, it does not provide a flexible platform for recapitulating clinically relevant missense mutations in vivo. To this end, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.